Latest Period
Q4 2025
Security Snapshot
Tyra Biosciences, Inc. - COMMON STOCK, $0.0001 PAR VALUE PER SHARE (TYRA) Institutional Ownership
CUSIP: 90240B106
13F Institutional Holders and Ownership History from Q3 2021 to Q1 2026
Institutions Reporting
133
Shares (Excl. Options)
56,830,609
Price
$26.29
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / COMMON STOCK, $0.0001 PAR VALUE PER SHARE
- Symbol
- TYRA on Nasdaq
- Shares outstanding
- 53,571,429
- Price per share
- $38.28
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 56,830,609
- Total reported value
- $1,493,991,866
- % of total 13F portfolios
- 0.02%
- Share change
- +133,090
- Value change
- +$12,760,989
- Number of holders
- 133
- Price from insider filings
- $38.28
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- TYRA - Tyra Biosciences, Inc. - COMMON STOCK, $0.0001 PAR VALUE PER SHARE is tracked under CUSIP 90240B106.
- 133 institutions reported positions in Q4 2025.
- 10 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 133 to 25 between Q4 2025 and Q1 2026.
- Reported value moved from $1,493,991,866 to $184,554,957.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 133 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 90240B106?
CUSIP 90240B106 identifies TYRA - Tyra Biosciences, Inc. - COMMON STOCK, $0.0001 PAR VALUE PER SHARE in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 90240B106:
Significant Owners of Tyra Biosciences, Inc. - COMMON STOCK, $0.0001 PAR VALUE PER SHARE (TYRA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 21% | -5.5% | $380,263,825 | +$11,370,397 | 12,266,575 | +3.1% | RA Capital Management, L.P. | 04 Mar 2026 |
| FMR LLC | 14% | +373% | $296,738,016 | +$231,353,566 | 7,747,648 | +354% | FMR LLC | 31 Mar 2026 |
| Commodore Capital LP | 6.3% | +22% | $47,216,250 | +$8,743,750 | 3,375,000 | +23% | Commodore Capital LP | 30 Sep 2025 |
| Farallon Capital Partners, L.P. | 5.6% | $93,723,285 | 2,984,818 | Dapice Joshua J. | 12 Feb 2026 | |||
| TCG Crossover GP I, LLC | 5.7% | $29,792,499 | 2,898,103 | TCG Crossover GP I, LLC | 27 Feb 2025 | |||
| JANUS HENDERSON GROUP PLC | 5.4% | +6% | $29,305,535 | +$1,672,924 | 2,856,290 | +6.1% | JANUS HENDERSON GROUP PLC | 30 Jun 2025 |
| Harris Todd | 5.1% | $85,416,403 | 2,814,379 | Todd Harris | 31 Dec 2025 | |||
| Vestal Point Capital, LP | 4.5% | -18% | $33,925,750 | -$6,363,058 | 2,425,000 | -16% | Vestal Point Capital, LP | 30 Sep 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 4% | -48% | $64,574,633 | -$55,131,655 | 2,127,665 | -46% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| Canaan XI L.P. | 1.4% | -68% | $28,725,000 | -$83,511,005 | 750,000 | -74% | Canaan XI L.P. | 31 Mar 2026 |
As of 31 Dec 2025, 133 institutional investors reported holding 56,830,609 shares of Tyra Biosciences, Inc. - COMMON STOCK, $0.0001 PAR VALUE PER SHARE (TYRA). This represents 106% of the company’s total 53,571,429 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Tyra Biosciences, Inc. - COMMON STOCK, $0.0001 PAR VALUE PER SHARE (TYRA) together control 98% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 23% | 12,198,625 | 0% | 3.3% | $320,701,851 |
| Nextech Invest, Ltd. | 7.6% | 4,055,861 | 0% | 10% | $106,628,586 |
| Alta Partners Management Company, L.P. | 7.1% | 3,823,425 | -6.3% | 97% | $100,517,843 |
| Commodore Capital LP | 6.3% | 3,375,000 | 0% | 5.9% | $88,728,750 |
| Canaan Partners XI LLC | 6.3% | 3,374,329 | -6.5% | 65% | $88,711,109 |
| JANUS HENDERSON GROUP PLC | 5.5% | 2,935,442 | +2.1% | 0.03% | $77,084,707 |
| TCG Crossover Management, LLC | 5.4% | 2,898,103 | 0% | 2.5% | $76,191,128 |
| Vestal Point Capital, LP | 4.5% | 2,425,000 | 0% | 2.3% | $63,753,250 |
| BVF INC/IL | 4% | 2,127,665 | -42% | 1.9% | $55,936,313 |
| BlackRock, Inc. | 3.9% | 2,086,423 | +12% | 0% | $54,852,060 |
| FARALLON CAPITAL MANAGEMENT LLC | 3.9% | 2,066,818 | +81% | 0.31% | $54,336,645 |
| VANGUARD GROUP INC | 2.9% | 1,572,785 | +3.5% | 0% | $41,348,518 |
| Kynam Capital Management, LP | 2.9% | 1,564,492 | -33% | 2.7% | $41,130,495 |
| 5AM Venture Management, LLC | 1.9% | 1,029,298 | +9.6% | 8.5% | $27,060,244 |
| Caligan Partners LP | 1.8% | 944,257 | +36% | 2.3% | $24,824,517 |
| Point72 Asset Management, L.P. | 1.6% | 874,192 | +210% | 0.04% | $22,982,508 |
| Balyasny Asset Management L.P. | 1.5% | 818,326 | -3.3% | 0.04% | $21,513,791 |
| STATE STREET CORP | 1.4% | 749,463 | +75% | 0% | $19,703,382 |
| MARSHALL WACE, LLP | 1.3% | 711,891 | +18% | 0.02% | $18,715,614 |
| Trails Edge Capital Partners, LP | 1.3% | 700,000 | 0% | 4.5% | $18,403,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.2% | 657,756 | +10% | 0% | $17,296,136 |
| Sio Capital Management, LLC | 0.98% | 526,002 | +2.1% | 2.3% | $13,828,593 |
| BOONE CAPITAL MANAGEMENT LLC | 0.74% | 398,482 | 3.3% | $10,476,092 | |
| Elmind Capital, LP | 0.65% | 350,000 | 0% | 2.7% | $9,201,500 |
| Eversept Partners, LP | 0.52% | 278,564 | +2.1% | 0.41% | $7,323,448 |
Institutional Holders of Tyra Biosciences, Inc. - COMMON STOCK, $0.0001 PAR VALUE PER SHARE (TYRA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 4,818,676 | $184,554,957 | -$99,948,890 | $38.30 | 25 |
| 2025 Q4 | 56,830,609 | $1,493,991,866 | +$12,760,989 | $26.29 | 133 |
| 2025 Q3 | 55,638,635 | $778,399,313 | -$9,877,671 | $13.99 | 115 |
| 2025 Q2 | 56,588,644 | $541,513,140 | +$28,813,504 | $9.57 | 120 |
| 2025 Q1 | 53,573,458 | $499,522,930 | +$34,676,031 | $9.30 | 116 |
| 2024 Q4 | 48,613,623 | $675,760,666 | -$145,254,713 | $13.90 | 112 |
| 2024 Q3 | 47,054,295 | $1,105,994,170 | +$8,152,750 | $23.51 | 94 |
| 2024 Q2 | 46,814,701 | $748,570,507 | -$1,810,347 | $15.99 | 76 |
| 2024 Q1 | 46,852,011 | $768,372,899 | +$182,484,246 | $16.40 | 75 |
| 2023 Q4 | 35,756,693 | $495,188,385 | -$9,797,725 | $13.85 | 62 |
| 2023 Q3 | 36,462,633 | $502,118,395 | +$3,284,853 | $13.77 | 59 |
| 2023 Q2 | 36,210,809 | $616,671,033 | +$8,028,494 | $17.03 | 59 |
| 2023 Q1 | 35,654,296 | $572,964,060 | +$8,455,742 | $16.07 | 50 |
| 2022 Q4 | 35,239,863 | $267,821,738 | -$5,207,345 | $7.60 | 45 |
| 2022 Q3 | 35,692,923 | $313,754,295 | -$403,922 | $8.79 | 43 |
| 2022 Q2 | 35,744,229 | $255,572,000 | -$3,322,156 | $7.15 | 44 |
| 2022 Q1 | 36,133,976 | $386,624,000 | -$8,627,515 | $10.70 | 46 |
| 2021 Q4 | 35,174,367 | $494,157,000 | +$13,654,547 | $14.07 | 45 |
| 2021 Q3 | 26,080,552 | $456,755,000 | +$456,755,000 | $17.59 | 25 |